由 Aveluro Research Team · 编辑政策
SRA（SRA）是一家在越南上市的Health Care公司，挂牌于HNX。该股最新成交价为 1,800 越南盾，当日基本持平，市值约 777.6 亿越南盾。
净资产收益率（ROE）为 -0.4%，反映公司运用股东资本的盈利能力，低于行业平均的 10.4%。每股收益约 -63 越南盾。
Aveluro 目前追踪 2 条与 SRA 相关的新闻，近期报道情绪偏负面（占比 100%）。最新的催化事件为「The Hà Nội Stock Exchange (HNX) announced that 53 stocks will be ineligible for margin trading in Q2/2026, effective April 10, 2026, due to various reasons such as warning status, negative profits, and potential delisting. This regulatory update will likely reduce liquidity and investor interest in these specific securities.」。Aveluro 综合模型对 SRA 的评分为 5.1/10（持有），综合了新闻情绪、价格动能与基本面。
当前重点
The Hà Nội Stock Exchange (HNX) announced that 53 stocks will be ineligible for margin trading in Q2/2026, effective April 10, 2026, due to various reasons such as warning status, negative profits, and potential delisting. This regulatory update will likely reduce liquidity and investor interest in these specific securities.
提示: 不构成投资建议。 · Aveluro 如何计算: Aveluro 结合提取的事件事实、来源可信度、股票背景和市场数据。评分是确定性研究信号，并非投资建议。
流动性较低 — 日均成交量偏薄，较大订单可能带来更宽买卖价差和价格冲击。